You are here: Industry Insights > GLP-1

News List

Polyethylene Glycol Loxenatide! The First Chinese-produced Long-acting GLP-1R Agonist PharmaSources/1℃
May 29, 2019
The blockbuster diabetes product: long-acting GLP-1 receptor agonist polyethylene glycol loxenatide (trade name: Fulaimei) of Hansoh Pharmaceutical has been marketed on May 7, 2019
Application to EMA filed for the approval of oral semaglutide europeanpharmaceuticalreview
April 30, 2019
It has been announced that a Marketing Authorisation Application (MAA) has been submitted to the European Medicines Agency (EMA) for oral semaglutide.
Second-Line Antidiabetic Meds May Impact Cardiovascular Risk drugs
December 29, 2018
For adults with type 2 diabetes initiating second-line antidiabetic medications (ADM), cardiovascular risk is increased with use of sulfonylureas or basal insulin versus newer ADM classes.....
Ajinomoto, XL-protein Forge Strategic Alliance contractpharma
December 19, 2018
Ajinomoto Bio-Pharma Services and XL-protein GmbH, a German biopharmaceutical company, have entered a Strategic Alliance, under which Ajinomoto will apply its Corynex expression system
Novo Nordisk's semaglutide is headed toward a Lilly showdown. Will Novo speed it up? fiercepharma
December 06, 2018
Novo Nordisk’s oral semaglutide is heading toward a market shake-up. And the company wants to see that happen sooner rather than later.
Novo keeps adding capacity, and jobs, to its North Carolina drug plant fiercepharma
December 06, 2018
Just months after announcing a $65 million expansion that will boost capacity at the North Carolina facility where it makes diabetes medications, Novo Nordisk says it needs yet more...
Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule americanpharmaceuticalreview
September 20, 2018
Oramed Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for human trials of its oral GLP-1 analog capsule ORMD-0901.
Novo Nordisk's oral GLP-1 analogue Ozempic bests Eli Lilly, Boehringer Ingelheim's Jardiance in late-stage trial firstwordpharma
May 30, 2018
Novo Nordisk announced headline results Tuesday from the Phase IIIa PIONEER 2 trial showing that a once-daily oral formulation of its GLP-1 analogue Ozempic (semaglutide) led to superior improvement in HbA1c levels in adults with type 2 diabetes
Victoza's triple-play CV nod sharpens Novo's edge against Trulicity fiercepharma
August 29, 2017
Victoza's new cardiovascular benefit approval gives it an edge over its new rival from Eli Lilly, Trulicity.
Novo Nordisk's new semaglutide trounces Lilly's scrappy Trulicity in diabetes trial fiercepharma
August 18, 2017
Novo Nordisk is counting on semaglutide, its forthcoming GLP-1 diabetes drug, to drive growth over the next few years, and data from the trial Sustain-7 should help.

Previous page 1 2 3 Next page